JPMorgan Chase & Co. lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 80.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 736,197 shares of the biopharmaceutical company's stock after purchasing an additional 327,936 shares during the period. JPMorgan Chase & Co. owned about 0.62% of Catalyst Pharmaceuticals worth $15,364,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. abrdn plc purchased a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $10,115,000. Vanguard Group Inc. raised its position in Catalyst Pharmaceuticals by 4.9% in the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock valued at $175,957,000 after purchasing an additional 390,116 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth $6,887,000. Skandinaviska Enskilda Banken AB publ grew its position in Catalyst Pharmaceuticals by 74.3% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 731,900 shares of the biopharmaceutical company's stock worth $15,421,000 after purchasing an additional 312,000 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in Catalyst Pharmaceuticals by 245.4% in the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company's stock valued at $7,990,000 after purchasing an additional 285,564 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.
Catalyst Pharmaceuticals Stock Performance
CPRX traded up $0.43 on Tuesday, hitting $23.23. 932,770 shares of the company were exchanged, compared to its average volume of 1,142,388. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $26.16. The firm has a market capitalization of $2.82 billion, a P/E ratio of 19.69, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79. The business's fifty day moving average is $22.62 and its 200 day moving average is $22.04.
Insider Activity at Catalyst Pharmaceuticals
In related news, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.
Analyst Ratings Changes
A number of research firms recently issued reports on CPRX. Stephens reissued an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Finally, Bank of America reaffirmed a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $32.29.
Get Our Latest Report on Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Company Profile
(
Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Featured Articles
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
